Strathclyde Minor Groove Binders (S-MGBs)

S-MGBs are novel, multi-targeted, broad spectrum anti-infective agents

The novel multi-targeted mode of action destroys the pathogen and shows resilience to the development of target based resistance.

  • Antimicrobial compound/strategy
  • Infection prevention
  • Antimicrobial stewardship
  • Microbial diagnostics
  • Removal antibiotics/bacteria

  • Bacteria
  • Viruses
  • Fungi
  • Yeasts
  • Parasites

  • Human
  • Veterinary
  • AgriFood
  • Environmental
  • Other

Development stage:
  • Research
  • Development
  • Validation
  • Market entry
  • Marketed product

  • Company
  • Academia
  • Institute
  • NGO
  • Government

  • License
  • Co-develop
  • Outsource
  • Joint Venture
  • Sell

Funding organisation:
  • OTHER / NA
  • CARB-X
  • FIND

Infectious disease area:
  • BSI
  • RTI
  • UTI
  • STI
  • GII
  • SSTI
  • CNSI
  • IAI
  • SSI

Geographic origin:
  • Eurasia
  • North America
  • South America
  • Africa
  • Oceania

We seek partners with drug development expertise and resources who share our goal of bringing new anti-infectives globally to patients who are underserved by existing choices, or where resistance is threatening the utility of current therapies.

Rostra Therapeutics is developing molecules into medicines to treat invasive fungal diseases and address AMR

S-MGBs are a platform technology with many molecules available for development to address a variety of infectious diseases. Our lead molecules are being developed for the treatment of invasive fungal disease.

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed